RNAC

6.1404.24%
PJ

Patrick J. Zenner

Lead Independent Director

Mr. Patrick J. Zenner, M.B.A., also known as Pat, has been an Advisor to Biotechnology & Pharmaceutical Companies since 2001. He serves as a Lead Independent Director since October 29, 2025 and is Independent Director of Cartesian Therapeutics, Inc. since June 2017 and served as its Lead Director from June 2018 to November 2019. Mr. Zenner served as the President and Chief Executive Officer of Hoffmann-La Roche Inc. from 1993 to January 2001. He served as the Chief Executive Officer of Curagen Corporation from May 23, 2005 to March 2006 and also served as its Interim Chief Executive Officer since May 12, 2005. He served as an Interim Chief Executive Officer at EXACT Sciences Corporation from July 2007 to March 2008. He served in various other capacities with Hoffman-LaRoche since 1969, including Senior Vice President of its pharmaceutical division from 1992 to 1993, Head of International Pharmaceutical Marketing from 1988 to 1992 and Vice President and General Manager of Roche Laboratories from 1982 to 1988. He is a 31-year veteran of the pharmaceutical industry and spent his entire career at Hoffmann-La Roche. He had been the Chairman of West Pharmaceutical Services, Inc. since July 01, 2015 until May 24, 2022 and also had been its Independent Director since July 2002 until May 24, 2022. He served as the Chairman of ArQule, Inc. since May 2004 until January 16, 2020. He served as the Chairman of Curagen Corporation from May 23, 2005 to March 2006 and also served as its Interim Chairman since May 12, 2005. He served as an Executive Chairman at EXACT Sciences Corporation from April 2008 to July 2010. He served as the Chairman of the HealthCare Institute of New Jersey. He has been an Independent Director of Cegedim Inc. since 2001. He served as an Independent Director at ArQule, Inc since 2002 until January 16, 2020. He serves as an Independent Director of Endotis Pharma SA and NextWave Pharmaceuticals Inc. He serves as a Member of Advisory Board at CellSpring. He had been an Independent Director of Selecta Biosciences, Inc. since June 16, 2017 and served as its Lead Independent Director since June 2018 until November 2019. He serves as a Member of Advisory Board at Christopher Reeve Paralysis Foundation. He served as a Member of Advisory Board of Hoffmann-La Roche Inc. He served as Director at Geron Corporation from July 2001 to May 19, 2010, Par Pharmaceutical Companies Inc from July 22, 2010 to September 28, 2012, Praecis Pharmaceuticals Inc. since July 2001, Genta Incorporated since December 2001, Exact Sciences Corporation from March 2003 to July 2010, Shionogi Pharma, Inc. since April 2002, XOMA Corporation from May 2002 to July 21, 2010 and CuraGen Corporation from July 2002 to October 1, 2009. He served as a Director of Gryphon Therapeutics, Inc., Hoffmann-La Roche and Neuro3d S.A. He served as a Director of the Pharmaceutical Research & Manufacturers of America (PhRMA) and the Biotechnology Industry Organization (BIO). He serves as a Trustee of Creighton University and Fairleigh Dickinson University. He serves as a Board Member of numerous associations including the Pharmaceutical Research and Manufacturers Association, the Health Care Institute of New Jersey, the American Society of Hospital Pharmacists Foundation, the Health Care Leadership Council and the Biotechnology Industry Organization. In addition, he has been a Member of numerous associations, including the American Foundation for Pharmaceutical Education, the Health Care Leadership Council. Mr. Zenner holds an MBA from Fairleigh Dickinson University and a B.S./B.A. from Creighton University and Bachelor of Science in Business Administration from Creighton University.

Positions